8-K: Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio, Inc. is implementing a 1-for-80 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement, with shares expected to trade on a split-adjusted basis starting September 11, 2026.

Summary

• Gossamer Bio, Inc. announced a 1-for-80 reverse stock split of its common stock, approved by stockholders on July 14, 2026.
• The reverse stock split is intended to help the company meet the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
• The split is expected to become effective on September 10, 2026, at 11:59 p.m. Eastern Time.
• Shares will trade on a split-adjusted basis starting September 11, 2026, under the symbol GOSS with a new CUSIP number.
• The number of authorized shares of common stock will be reduced from 4,000,000,000 to 50,000,000.
• Fractional shares will be rounded up to the nearest whole share.
• Adjustments will be made to convertible notes, warrants, and equity awards to reflect the split ratio.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the reverse stock split is a measure often taken by companies struggling to meet exchange listing requirements, indicating underlying financial or market performance issues.

Positives

• The reverse stock split is intended to help Gossamer Bio regain compliance with the Nasdaq minimum bid price requirement, potentially avoiding delisting.
• Shareholder ownership percentages will remain largely unchanged, except for minor adjustments due to fractional share treatment.
• The company is rounding up fractional shares to the nearest whole share, which benefits shareholders who would otherwise receive a fraction.

Negatives

• The necessity of a reverse stock split often signals underlying issues with the company's stock performance and market valuation.
• The significant reduction in authorized shares (from 4 billion to 50 million) could limit future capital raising flexibility.
• The reverse stock split may not result in a sustained increase in the stock price or ensure continued Nasdaq listing.

Risks

• The reverse stock split may not result in a sustained increase in the price of the Company's Common Stock and may not satisfy the Nasdaq minimum bid price requirement.
• Any delay in the planned reverse stock split.
• The reverse stock split may impact the company's results of operations, business operations, and reputation, as well as the trading prices and volatility of the common stock.
• Unstable market and economic conditions and changes in healthcare legislation, tariffs, and trade policies may adversely affect the Company's business and financial condition and the broader economy and biotechnology industry.

Future Outlook

The reverse stock split is intended to help the Company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. However, there is a risk that the split may not result in a sustained increase in the stock price or satisfy the Nasdaq requirement. Adjustments will be made to convertible notes, warrants, and equity awards to reflect the new ratio.

Management Comments

• The reverse stock split is intended to help the Company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often viewed negatively, tactic in the biotechnology sector when companies face delisting due to low stock prices. This often reflects challenges in clinical development progress or market sentiment.

Stakeholder Impact

• Shareholders will see their number of shares reduced by a factor of 80, but their percentage ownership will remain largely the same, except for fractional share adjustments.
• Holders of convertible notes, warrants, and equity awards will have their terms adjusted proportionally to reflect the 1-for-80 split.
• The Nasdaq exchange will be impacted by the company's attempt to regain compliance with listing standards.

Next Steps

• Shares of Common Stock will begin trading on a split-adjusted basis on the Nasdaq Global Select Market at market open on September 11, 2026.
• The number of authorized shares of Common Stock will be reduced from 4,000,000,000 to 50,000,000.
• The total number of authorized shares of capital stock will be reduced from 4,070,000,000 to 120,000,000.
• Conversion rates of convertible notes, exercise prices and numbers of shares for warrants and equity awards will be adjusted.

Key Dates

Recommendation

The reverse stock split is a defensive measure to maintain Nasdaq listing, not a sign of fundamental business improvement. While it addresses the immediate listing requirement, it does not resolve underlying operational or clinical development challenges. Therefore, a 'hold' recommendation is appropriate pending further positive developments in the company's pipeline or financial performance.

Keywords

Reverse Stock Split, Nasdaq Compliance, Biopharmaceutical, Authorized Shares, Stock Adjustment, Convertible Notes, Warrants, Equity Awards